CA2668689C - Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto - Google Patents

Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto Download PDF

Info

Publication number
CA2668689C
CA2668689C CA2668689A CA2668689A CA2668689C CA 2668689 C CA2668689 C CA 2668689C CA 2668689 A CA2668689 A CA 2668689A CA 2668689 A CA2668689 A CA 2668689A CA 2668689 C CA2668689 C CA 2668689C
Authority
CA
Canada
Prior art keywords
compound
dimethoxy
hexahydro
pyrido
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2668689A
Other languages
English (en)
French (fr)
Other versions
CA2668689A1 (en
Inventor
Kyle W. Gano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39110526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2668689(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CA2668689A1 publication Critical patent/CA2668689A1/en
Application granted granted Critical
Publication of CA2668689C publication Critical patent/CA2668689C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2668689A 2006-11-08 2007-11-08 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto Active CA2668689C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86494406P 2006-11-08 2006-11-08
US60/864,944 2006-11-08
PCT/US2007/084176 WO2008058261A1 (en) 2006-11-08 2007-11-08 Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto

Publications (2)

Publication Number Publication Date
CA2668689A1 CA2668689A1 (en) 2008-05-15
CA2668689C true CA2668689C (en) 2015-12-29

Family

ID=39110526

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2668689A Active CA2668689C (en) 2006-11-08 2007-11-08 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto

Country Status (16)

Country Link
US (2) US8039627B2 (esLanguage)
EP (1) EP2081929B1 (esLanguage)
JP (1) JP5290185B2 (esLanguage)
KR (1) KR101500766B1 (esLanguage)
CN (1) CN101553487B (esLanguage)
AU (1) AU2007317242B2 (esLanguage)
BR (1) BRPI0718247B1 (esLanguage)
CA (1) CA2668689C (esLanguage)
DK (1) DK2081929T3 (esLanguage)
EA (1) EA018378B1 (esLanguage)
ES (1) ES2402220T3 (esLanguage)
IL (1) IL198250A0 (esLanguage)
MX (1) MX2009004910A (esLanguage)
PL (1) PL2081929T3 (esLanguage)
PT (1) PT2081929E (esLanguage)
WO (1) WO2008058261A1 (esLanguage)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2081929E (pt) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados
NO3061760T3 (esLanguage) 2008-09-18 2018-04-07
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012000308A1 (zh) * 2010-06-29 2012-01-05 中国药科大学 丁苯那嗪的拆分方法
US8351329B2 (en) * 2010-09-14 2013-01-08 Cisco Technology, Inc. Universal load-balancing tunnel encapsulation
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
HK1219095A1 (zh) * 2013-01-31 2017-03-24 Auspex Pharmaceuticals, Inc. Vmat2的benzoquinolone抑制剂
US20160207917A1 (en) * 2013-09-27 2016-07-21 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
BR112016012747B1 (pt) 2013-12-03 2022-07-12 Auspex Pharmaceuticals, Inc Processo de preparação de uma mistura racêmica de (rr,ss)-d6-tetrabenazina
MX2016009817A (es) * 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
CN106061506A (zh) 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
RS59559B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
FI3936130T3 (fi) * 2014-05-06 2024-04-23 Neurocrine Biosciences Inc Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
EP3253752B1 (en) * 2015-02-06 2023-08-16 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
CN114767672A (zh) 2015-03-06 2022-07-22 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
AU2016282790B9 (en) * 2015-06-23 2020-01-30 Neurocrine Biosciences, Inc. VMAT2 inhibitors for treating neurological diseases or disorders
HUE070538T2 (hu) 2015-08-12 2025-06-28 Incyte Holdings Corp Egy LSD1 inhibitor sói
EP3359148A1 (en) 2015-10-09 2018-08-15 Teva Pharmaceuticals International GmbH Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease
MY193767A (en) * 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
US10160757B2 (en) * 2015-12-23 2018-12-25 Neuroscrine Biosciences, Inc. Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
US10479787B2 (en) 2016-04-22 2019-11-19 Lupin Limited Process for preparation of tetrabenazine and deutetrabenazine
WO2018001335A1 (zh) 2016-06-29 2018-01-04 苏州科睿思制药有限公司 Nbi-98854的晶型及其制备方法和用途
WO2018067945A1 (en) * 2016-10-06 2018-04-12 Assia Chemical Industries Ltd. Solid state forms of valbenazine
EP4400171A3 (en) 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
MX394415B (es) * 2017-01-27 2025-03-24 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2).
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018170214A1 (en) 2017-03-15 2018-09-20 Zhang Chengzi Analogs of deutetrabenazine, their preparation and use
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018178243A2 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
US20200230127A1 (en) * 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CN111343985A (zh) * 2017-11-08 2020-06-26 逸达生物科技股份有限公司 二氢丁苯那嗪的酯
US11384077B2 (en) 2017-11-22 2022-07-12 Assia Chemical Industries Ltd. Solid state form of Valbenazine
US11339158B2 (en) 2017-12-26 2022-05-24 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
CN110092785A (zh) * 2018-01-31 2019-08-06 广东东阳光药业有限公司 一种丁苯那嗪的动态拆分方法
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
KR20210021006A (ko) 2018-06-14 2021-02-24 뉴로크린 바이오사이언시즈 인코퍼레이티드 Vmat2 억제제 화합물, 조성물 및 그와 관련된 방법
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
CA3065236A1 (en) 2018-12-27 2020-06-27 Apotex Inc. Novel crystalline form of valbenazine dibesylate
WO2020213014A1 (en) 2019-04-19 2020-10-22 Mylan Laboratories Limited An improved process for the preparation of valbenazine and its salts
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
KR20220035204A (ko) * 2019-08-12 2022-03-21 산동 루예 파마슈티칼 컴파니 리미티드 Vmat2 억제제 및 이의 제조 방법 및 용도
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN114423755A (zh) 2019-09-13 2022-04-29 纽罗克里生物科学有限公司 用于合成缬苯那嗪的方法
CN110698397A (zh) * 2019-10-28 2020-01-17 南京红杉生物科技有限公司 丁苯那嗪中间体及其合成方法、应用和合成用中间产物
AR125188A1 (es) 2021-03-22 2023-06-21 Neurocrine Biosciences Inc Inhibidores del vmat2 y métodos de uso
US20240239791A1 (en) 2021-04-26 2024-07-18 Neurocrine Biosciences, Inc. Processes for the synthesis of valbenazine
MX2023014977A (es) 2021-06-30 2024-02-09 Neurocrine Biosciences Inc Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral.
IL309172A (en) 2021-06-30 2024-02-01 Neurocrine Biosciences Inc Vulbanazine for use in the additional treatment of schizophrenia
EP4489754A1 (en) 2022-03-07 2025-01-15 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
CA3267926A1 (en) 2022-09-21 2024-03-28 Neurocrine Biosciences, Inc. HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025199234A1 (en) 2024-03-20 2025-09-25 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US2843591A (en) * 1958-07-15 Method for preparing same
US2852518A (en) * 1957-05-23 1958-09-16 Parke Davis & Co Di-substituted quinoline compounds
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
US20090202428A1 (en) 2005-06-29 2009-08-13 Paul Harris Use of Dtbz for Imaging Endocrine Pancreas and Beta Cell Mass In Type 1 Diabetes
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110257220A1 (en) 2005-08-06 2011-10-20 Cambridge Laboratories (Ireland) Limited 3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses
PT2081929E (pt) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados

Also Published As

Publication number Publication date
US8357697B2 (en) 2013-01-22
KR20090079257A (ko) 2009-07-21
ES2402220T3 (es) 2013-04-29
US20120077839A1 (en) 2012-03-29
WO2008058261A1 (en) 2008-05-15
IL198250A0 (en) 2009-12-24
BRPI0718247B1 (pt) 2021-09-21
PT2081929E (pt) 2013-04-15
KR101500766B9 (ko) 2024-09-25
EP2081929B1 (en) 2013-01-09
BRPI0718247A2 (pt) 2014-01-07
AU2007317242A1 (en) 2008-05-15
CN101553487A (zh) 2009-10-07
AU2007317242B2 (en) 2013-08-01
JP2010509366A (ja) 2010-03-25
MX2009004910A (es) 2009-07-24
ES2402220T8 (es) 2021-12-23
US8039627B2 (en) 2011-10-18
EP2081929A1 (en) 2009-07-29
EA018378B1 (ru) 2013-07-30
KR101500766B1 (ko) 2015-03-16
CA2668689A1 (en) 2008-05-15
DK2081929T3 (da) 2013-04-15
US20080167337A1 (en) 2008-07-10
PL2081929T3 (pl) 2013-06-28
JP5290185B2 (ja) 2013-09-18
CN101553487B (zh) 2012-06-13
EA200970461A1 (ru) 2009-12-30

Similar Documents

Publication Publication Date Title
CA2668689C (en) Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
ES2878054T3 (es) Espiroheptanil hidantoínas como inhibidores de ROCK
CA2904820A1 (en) Pyridinylpyrazoloquinoline compound
CA3163933A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP1154988B1 (en) Mevinolin derivatives
CA3103120A1 (en) Chemical compounds
BR112018013955B1 (pt) Compostos ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido [2,3- d] azepina, composição farmacêutica que os compreende e uso dos mesmos
FI113769B (fi) Neurosuojaavia kromaaniyhdisteitä
US10501466B2 (en) WDR5 inhibitors and modulators
EP3867244B1 (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
CN118302418A (zh) 一种芳杂环类化合物及其应用
CN111356677B (zh) 四氢异喹啉类衍生物及其制备方法和用途
EP3980401B1 (en) Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders
EP3866854B1 (en) 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament
EP3867245B1 (en) 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
Xi et al. Drug metabolism-based design, synthesis, and bioactivities of 1-(2, 6-dimethylphenoxy)-2-(3, 4-dimethoxyphenylethylamino) propane hydrochloride (DDPH) analogs as α1-adrenoceptors antagonists
CN119912454A (zh) 抗肿瘤化合物及其制备方法和用途
CN121532384A (zh) 嘧啶化合物及其作为usp1抑制剂的用途
WO2020246487A1 (ja) ジスピロジケトピペラジン構造を有する化合物
HK40033047A (en) Imidazopyridine derivatives and the use thereof as medicament
HK40033047B (en) Imidazopyridine derivatives and the use thereof as medicament
HK40059626B (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
HK40059626A (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
CA3008653A1 (en) Bruton's tyrosine kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request